Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Change in Receivables (2021 - 2025)

Kiniksa Pharmaceuticals International (KNSA) has disclosed Change in Receivables for 5 consecutive years, with -$36.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Receivables fell 314.71% year-over-year to -$36.1 million, compared with a TTM value of -$26.1 million through Dec 2025, down 227.73%, and an annual FY2025 reading of -$26.1 million, down 227.73% over the prior year.
  • Change in Receivables was -$36.1 million for Q4 2025 at Kiniksa Pharmaceuticals International, down from $19.8 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $25.5 million in Q1 2022 and bottomed at -$36.1 million in Q4 2025.
  • Average Change in Receivables over 5 years is $720444.4, with a median of $1.1 million recorded in 2021.
  • Peak annual rise in Change in Receivables hit 1114.19% in 2023, while the deepest fall reached 744.85% in 2023.
  • Year by year, Change in Receivables stood at $686000.0 in 2021, then soared by 118.8% to $1.5 million in 2022, then soared by 1114.19% to $18.2 million in 2023, then dropped by 7.62% to $16.8 million in 2024, then tumbled by 314.71% to -$36.1 million in 2025.
  • Business Quant data shows Change in Receivables for KNSA at -$36.1 million in Q4 2025, $19.8 million in Q3 2025, and -$8.2 million in Q2 2025.